Form D · Pharmaceuticals

Euclises Pharmaceuticals, Inc.

St. Louis, MO · CIK 0001550350

Offering snapshot reported Dec 1, 2016 · SEC filing

Reported sold
$1.22M
Offering amount: $2.71M
Investors reported
5
Form D · investor count
Minimum accepted
$1
Reported outside-investor minimum
First sale
Nov 9, 2015
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported investors0 → 5

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 1, 2016Amendment$1,216,913No comparison5SEC filing
Oct 1, 2015Amendment$1,851,250$1,551,250vs Jan 13, 20149SEC filing
Oct 1, 2015InitialYet to sellNo comparison0SEC filing
Jan 13, 2014Initial$300,000No comparison1SEC filing
May 17, 2012Initial$174,998No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06c
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-248588

Source: Form D, filed Dec 1, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert A. Beardsley Director
Charles A. Bolten Director
Robert J. Calcaterra Director
Rajesh Devraj Director
Robert W. Karr Director, Executive
Eduardo J. Martinez Director
Rick Ryan Director
Bobby W. Sandage, Jr. Director, Executive
John J. Talley Director
Randy H. Weiss Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
4320 Forest Park Avenue, Suite 303
St. Louis, MO, 63108